Updated:
Agios Pharmaceuticals
Agios Pharmaceuticals was founded in 2007 by Todd Golub, the director of the Broad Institute's cancer program, and hematologist-oncologist David...
Agios Pharmaceuticals
Agios Pharmaceuticals was founded in 2007 by Todd Golub, the director of the Broad Institute's cancer program, and hematologist-oncologist David Schenkein, who built the company around the emerging science of cellular metabolism. The firm focused on genetically defined cancers and inborn errors of metabolism — a narrow, high-risk mandate centered on enzymes and pathways most biopharma firms ignored. The company went public in 2013 and commercialized its first drug, TIBSOVO (ivosidenib) for IDH1-mutated acute myeloid leukemia, in 2018. The company's pipeline concentrated on pyruvate kinase activators, a class of drugs that boost red blood cell energy production, leading to its approved therapy PYRUKYND (mitapivat) for hemolytic anemia in adults with pyruvate kinase deficiency. Agios sold its oncology portfolio to Servier Pharmaceuticals for $1.8 billion upfront in 2021, alongside royalties and milestones, narrowing its focus entirely to rare hematologic diseases. The deal financed ongoing clinical programs for mitapivat in thalassemia and sickle cell disease, while leaving Agios cash-rich and streamlined. The firm operates in the U.S. with an international footprint through Servier partnerships and its own European filings. As of 2023, Agios employed roughly 350 people headquartered in Cambridge, Massachusetts under CEO Brian Goff, a former Johnson & Johnson and Alexion executive who joined in 2020. The company operates without a separate venture arm or philanthropic vehicle; it functions as a publicly traded biotech rather than a family office or investment manager. In February 2024, Agios acquired global development and commercial rights to vorasidenib (Servier’s brain-penetrant IDH inhibitor) for $100 million upfront, marking a re-expansion into oncology adjacent to its metabolic expertise. Agios occupies a distinct hybrid position: it behaves like a focused rare-disease biotech but carries the platform-like capacity to pivot between oncology and hematology around a core metabolic thesis. That thesis — drugging cellular energetics — remains unusual and unduplicated at commercial stage, leaving the firm with few direct public-company comparables and a survival story that involved jettisoning its most visible asset class to preserve its scientific identity.
General information
Firm type
other
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
88 Sidney Street, Cambridge, MA 02139, United States
Principals
David Schenkein
Co-founder
Todd Golub
Co-founder
Susan Pandya
Head of Cancer Metabolism and Vice President of Clinical Development
Brian Goff
Chief Executive Officer
Sector focus
Frequently asked questions
How does Agios define its therapeutic focus post-oncology divestiture?
Since selling its cancer portfolio to Servier for $1.8 billion in 2021, Agios concentrates on genetically defined hematologic diseases — specifically pyruvate kinase deficiency, thalassemia, and sickle cell disease — around its lead drug PYRUKYND (mitapivat). The firm retains deep metabolic science expertise and may re-enter oncology through targeted licensing, as seen with its February 2024 acquisition of vorasidenib from Servier.
Who runs development decisions at Agios?
CEO Brian Goff (since 2020) leads corporate strategy, while clinical development occurs under Chief Medical Officer Sarah Gheuens and a team of disease-area VPs. Founder David Schenkein departed day-to-day operations but remains a strategic influence; Todd Golub's Broad Institute continues to feed early-stage biology into the company's metabolic platform thinking.
Is Agios a single-family office or investment vehicle?
No. Agios Pharmaceuticals, Inc. is a public biotech company (NASDAQ: AGIO). It is not a family office, private investment firm, or asset manager. Its capital comes from equity financings and commercial drug revenue, not a single family's wealth.
Does Agios participate in fund commitments or venture investing?
Agios does not operate a venture arm or make third-party fund commitments. Its capital deployment is entirely directed at internal clinical programs and occasional asset acquisitions like the vorasidenib deal from Servier. It functions as an operating pharmaceutical company, not an allocator.
What rare disease pipeline assets does Agios currently hold?
The commercial asset is PYRUKYND (mitapivat), approved for pyruvate kinase deficiency and in Phase 3 for thalassemia and sickle cell disease. In February 2024, Agios added vorasidenib, a brain-penetrant IDH inhibitor in late-stage development for IDH-mutant glioma. Earlier-stage programs include novel pyruvate kinase activators and additional metabolic targets.
How does Agios source its early-stage biology?
Co-founder Todd Golub's position as director of the Broad Institute's Cancer Program historically provided a unique sourcing nexus: academic discoveries in cellular metabolism that lacked pharmaceutical champions. Though the pipeline is now clinical-stage, the firm's metabolism-first mandate traces back to Broad Institute biology that Golub and Schenkein translated into drug discovery programs.
Where does Agios's current financial runway come from?
The $1.8 billion Servier oncology sale in 2021 left Agios overfunded relative to its hematology pipeline, with roughly $800 million in cash and equivalents on hand as of year-end 2023. This balance sheet supports mitapivat's Phase 3 programs, the vorasidenib acquisition, and exploratory R&D without near-term capital-market dependence.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: